The biotechnology sector is showing renewed signs of life, with improving funding conditions, increased M&A activity and a stronger focus on companies advancing high-quality clinical programs. As sentiment shifts back towards innovation and execution, the next generation of drug developers could present compelling opportunities for long-term investors.
“Taking on a challenge is a lot like riding a horse; if you’re comfortable while you’re doing it, you’re probably doing it wrong.” — Ted Lasso
In this latest article, Portfolio Manager Anthony Kavanagh explores why the environment for drug developers is improving, what is driving renewed investor interest, and the characteristics they believe separate the most promising companies from the rest.
Click here to read the full article on Livewire.
Click here to download the PDF version.
Updated: 06 Aug 2026
